Mergen Becomes Latest to Settle with OGT; Launches OEM Array Business | GenomeWeb

Mergen last week became the latest player in the microarray industry to settle litigation with Oxford Gene Technology, and the firm wasted no time in trying to drum up business by offering an OEM service for DNA arrays.

The dispute dates back to December 2002, when OGT filed suit against several firms, including Mergen, for patent infringement. Like the other firms, Mergen filed a countersuit but also entered into discussions with OGT to settle out of court.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.